Lantern Pharma Inc. (LTRN)
NASDAQ: LTRN · Real-Time Price · USD
2.820
-0.020 (-0.70%)
At close: Feb 27, 2026, 4:00 PM EST
2.870
+0.050 (1.77%)
After-hours: Feb 27, 2026, 7:34 PM EST
Lantern Pharma Employees
Lantern Pharma had 24 employees as of December 31, 2024. The number of employees increased by 3 or 14.29% compared to the previous year.
Employees
24
Change (1Y)
3
Growth (1Y)
14.29%
Revenue / Employee
n/a
Profits / Employee
-$788,351
Market Cap
31.54M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 24 | 3 | 14.29% | 24 | 0 |
| Dec 31, 2023 | 21 | -2 | -8.70% | 21 | 0 |
| Dec 31, 2022 | 23 | 7 | 43.75% | 22 | 1 |
| Dec 31, 2021 | 16 | 1 | 6.67% | 14 | 2 |
| Dec 31, 2020 | 15 | 8 | 114.29% | 11 | 4 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Passage Bio | 60 |
| Werewolf Therapeutics | 39 |
| AN2 Therapeutics | 22 |
| INmune Bio | 22 |
| Tempest Therapeutics | 21 |
| ABVC BioPharma | 19 |
| NeuroSense Therapeutics | 17 |
| Outlook Therapeutics | 17 |
LTRN News
- 18 days ago - Lantern Pharma to Present at the 7th Glioblastoma Drug Development Summit in Boston on February 17-19, 2026 - Business Wire
- 5 weeks ago - Lantern Pharma's LP-284 Receives FDA Orphan Drug Designation for Soft Tissue Sarcomas - Business Wire
- 6 weeks ago - Lantern Pharma Announces Establishing an A.I. Center of Excellence in India to Industrialize the RADR® Platform and Accelerate Global Development Opportunities with BioPharma Companies - Business Wire
- 3 months ago - Lantern Pharma Reports Additional Positive LP-184 Phase 1a Results Showing Durable Disease Control in Heavily Pre-Treated Advanced Cancer Patients as Company Advances Precision Oncology Program into Multiple Biomarker-Guided Phase 1b/2 Trials - Business Wire
- 3 months ago - Lantern Pharma Inc. (LTRN) Discusses LP-184 Phase 1a Clinical Results and Implications for DNA Damage Repair-Deficient Tumors Transcript - Seeking Alpha
- 3 months ago - Lantern Pharma Inc. (LTRN) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Lantern Pharma Reports Third Quarter 2025 Financial Results and Provides Business Updates - Business Wire
- 4 months ago - Lantern Pharma to Report Third Quarter 2025 Operating & Financial Results on November 13th, 2025 at 9:00 a.m. ET - Business Wire